Today, cell and gene therapies can cure or transform many blood cancers and genetic diseases , but access is limited by cost, centralised manufacturing, and regulatory complexity. Most hospitals, especially in emerging regions, cannot raise the capital or build the systems required to participate.
Immuna changes this by acting as a full-stack implementation and commercialization partner for hospitals and health systems.
+41 79 889 81 63
Most hospitals lack the resources to raise funds or navigate regulatory hurdles. Immuna provides co-investment and revenue-sharing frameworks in hospitals with committed clinical leadership, using a Build–Own–Operate–Transfer (BOOT) model.
Immuna sets up regional manufacturing and quality hubs through BOOT to navigate complex supply chains and GMP bottlenecks, supporting local or near-site CAR-T and gene therapy production.
Immuna manages regional and global compliance and approvals, navigating fragmented regulatory systems so clinicians and hospitals can focus on care delivery instead of paperwork.
Immuna ensures commercialization and scalability via Swiss governance and operational efficiency, and takes responsibility for ROI accountability for hospital management through a hub-and-spoke model for regional rollout.
For more than three decades, the scientific leadership behind Immuna has been closely connected with pioneers who helped shape the field of cellular and gene therapy. Members of this ecosystem have contributed to the design and manufacturing of the world’s first clinically deployed lentiviral vectors—technologies that went on to support the first FDA-authorized immunotherapy trials using lentiviral delivery systems.
This deep technical lineage—spanning vector engineering, GMP manufacturing, regulatory engagement, and real-world clinical translation—forms the scientific foundation upon which Immuna is built. The experience accumulated over 30+ years across leading academic centres, biomanufacturing facilities, and clinical research programs ensures that Immuna’s platforms are grounded in rigorous science, proven technologies, and globally validated development pathways.
We work with multiple vendors, platforms, and equipment choices , always aiming for freedom-to-operate and affordability.
Local or regional GMP units integrated into health systems – not a single distant mega-facility.
Swiss-anchored governance with carefully designed pathways into Indian, African, ASEAN, GCC and Latin American regulatory systems.
For-profit, but mission-driven, with affordability and public health impact built into the model from day one.
Boro Dropulic
Boro holds a PhD from the University of Western Australia and an MBA from the Johns Hopkins University (JHU). He has been involved in gene therapy since the late 1980s.
Seeing a need for improved business models to support the affordability and accessibility of gene therapy products, Boro co-founded Caring Cross and serves as our Executive Director.
Pradeep Kakkattil
Global health and innovations leader. Co-founder of Health Innovation Exchange (HIEx) a unique platform connecting political leadership with innovators and investors for healthcare access which over last 2 years has facilitated over US200m in investments;
Co-founder of the Women in Innovation Fund (WiNFUND) which advocates, invests and supports acceleration of female health entrepreneurship in Africa and Asia;
Co-founder of Technical Support Facility (TSF) and built it to be the largest TA mechanism of the UN in HIV;
Dr. Biju Jacob
Experienced leader in innovation strategy, research infrastructure and start-up advisory with a decade of experience in early-stage discovery, clinical research and regulatory affairs. Worked in both large organizations and start-ups with deep medical research & management experience.
He is a recipient of BIRAC Innovation 2014 award, ISBA National award for entrepreneurship 2010 and CV Raman Young Scientist Awards 2007
Phani Sripada
Seasoned information security leader with over a decade of experience driving strategic initiatives at the intersection of Digital Transformation, Cybersecurity, Sustainability, and Corporate Digital Responsibility (CDR). As Chief Information Security Officer at Gavi, the Vaccine Alliance, I spearhead security strategies, risk management, and compliance to protect critical systems supporting global health and immunization.
Sekhar Bollina
Sekhar Bollina is a seasoned strategic advisor with over 20 years of experience supporting global organizations in shaping their long-term vision and driving enterprise growth.
He works closely with leadership teams to define priorities, strengthen organizational alignment, and create frameworks for sustainable value creation. Sekhar is recognized for his forward-looking perspective and ability to translate complex challenges into clear strategic direction.
Dr. Andrew Nerlinger
Dr. Andrew Nerlinger is a physician, venture capital investor, and social impact innovator. Andrew is the Executive Director of the Global Health Security Fund, a Geneva-based nonprofit that supports impact investment in global health security innovation.
He also serves as the Chair of the Board of Directors of the Global Health Security Network (GHSN), an Australia-based nonprofit that organizes the biennial Global Health Security Conference.
Andrew is a Venture Partner at Bill Wood Ventures, an Austin-based family office that invests in early stage technology companies, and is a Co-founder of PandemicTech, an Austin-based venture philanthropy launched in 2016 that supports health security innovators on the front lines of fighting pandemic infectious disease threats.
He is a graduate of the Yale University School of Medicine (MD) and the University of Notre Dame (BS, mathematics and philosophy).
Prof. Hans-Florian Zeilhofer
Professor Hans-Florian Zeilhofer was heading the departments of oral and cranio-maxillofacial surgery at the University Hospital Basel and the Cantonal Hospital Aarau, as well as the High-Tech Research Centre at the Department of Biomedical Engineering in the Faculty of Medicine, University of Basel until 2020. After studying human medicine, dentistry and philosophy, he trained as a specialist in oral and maxillofacial surgery. In June 2002, he joined the University of Basel. In 2004 he established and headed the High-Tech Research Centre at the University Hospital Basel. Since 2013 he has been establishing the Med-Tech Innovation Hive in Basel. From 2017 to 2022 he was appointed Associated Vice President of Innovation at the University of Basel. He has received numerous honours and awards for his innovative research work. He holds a number of international patents and has created several startup companies in recent years out of high-tech innovations from university research.
Jamie Taylor
Jami Taylor is a Managing Director at Stanton Park Capital, an M&A advisory firm servicing the middle market. Previously, Jami held global leadership roles across Johnson & Johnson, where her responsibilities included evaluation and execution of external partnerships in support of R&D and commercial objectives. Jam
She holds a Master of Business Administration from the Kellogg School of Management at Northwestern University, a Master of Liberal Arts degree from Harvard University, a Certificate in Executive Leadership from the Graduate School of Management at Cornell University, and a Bachelor of Arts degree with Distinction from the University of Virginia.
Dr. Yoshinobu Nagamine
Dr Yoshinobu Nagamine is a global health and strategic partnerships executive with more than 20 years of international experience spanning public health, innovation, humanitarian affairs, and innovative financing. At Gavi, the Vaccine Alliance, he mobilized over USD 700 million in public-sector funding and built partnerships across governments, multilateral organizations, foundations, and the private sector.
Prior to Gavi, he held leadership positions with the International Committee of the Red Cross (ICRC) and the International Organization for Migration (IOM), working across Europe, Asia, Africa, and conflict-affected settings. He has extensive experience in stakeholder engagement, market access, fundraising, and public-private partnerships.
Yoshinobu holds an MBA from IMD Lausanne, a PhD in Human Security from the University of Tokyo, and an MA from the Graduate Institute of International and Development Studies in Geneva. He is a World Economic Forum Young Global Leader and speaks English, Japanese, French, and German.